Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New vaccine boosts breast cancer treatment before surgery

NCT ID NCT05325632

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times

Summary

This study tests whether adding a special vaccine (dendritic cell vaccine) to standard chemotherapy and targeted therapy can improve outcomes for people with HER2-positive breast cancer. About 53 participants with early-stage breast cancer will receive the vaccine alongside standard drugs before surgery. The goal is to see if the vaccine helps the immune system fight the cancer more effectively, leading to a complete response in the breast and lymph nodes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.